0J9P.L - Incyte Corporation

LSE - LSE Prezzo differito. Valuta in USD.
62,58
+0,04 (+0,07%)
Al 02:30PM BST. Mercato aperto.
Il grafico dei titoli non è supportato dal tuo browser attuale
Chiusura precedente62,54
Aperto62,58
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno62,58 - 62,58
Intervallo di 52 settimane60,83 - 85,93
Volume200
Media Volume12.391
Capitalizzazione136,437M
Beta (5 anni mensile)0,72
Rapporto PE (ttm)0,15
EPS (ttm)4,20
Prossima data utili31 lug 2023 - 04 ago 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil

    MONTREAL, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for tafasitamab in combination with lenalidomide to ANVISA, the Brazilian health regulatory agency, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for auto